Myokardia Inc (MYOK) Return on Equity ROE from the third quarter 2020 to third quarter 2019 and annually, average high and low, overall ranking from Sep 30 2020 to Sep 30 2019 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Myokardia Inc   (NASDAQ: MYOK)

Myokardia Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Myokardia Inc in the third quarter 2020?
Myokardia Inc recorded a cumulative net loss of $-277 million during 12 months ending in the third quarter 2020, resulting in a negative return on equity (ROE) of -44.16%.

Within the Major Pharmaceutical Preparations industry 149 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2020 from 0 to 3221.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2020)
III. Quarter		 (Jun 30 2020)
II. Quarter		 (Mar 31 2020)
I. Quarter		 (Dec 31 2019)
IV. Quarter		 (Sep 30 2019)
III. Quarter
Y / Y Equity Change 86.8 % 55.54 % -42.95 % 9.64 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -277 -334 -309 -276 -233
Return On Equity (TTM) -44.16 % -63.13 % -68.89 % -53.77 % -46.18 %
MYOK's Total Ranking # 3221 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 845 909 349 406 452
Seq. Equity Change -7.01 % 160.28 % -14.07 % -10.19 % -22.57 %
Seq. Net Income Change - - - - -

Back to MYOK Management Effectiveness >> MYOK's 5 Years Annual ROE >> Compare MYOK ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 150
Sector # 393
Overall # 3221

Return On Equity Statistics
High Average Low
-2.22 %
-30.88 %
-68.89 %
(Dec 31 2016)   (Mar 31 2020)





MYOK Annual Return On Equity (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016		 (Dec 31 2015)
2015
Total Equity in Millions 406 371 242 145 94
Y / Y Equity Change 9.64 % 53.3 % 66.28 % 54.87 % -
Net Income in Millions -276 -68 -46 -13 -23
Y / Y Net Income Change - - - - -
Return On Equity -67.99 % -18.27 % -19.01 % -9.05 % -24.44 %

Back to MYOK Management Effectiveness >> MYOK's 5 Years Annual ROE >> Compare MYOK ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MYOK's' Return on Equity at Yahoo Finance
MYOK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MYOK's Competitors
Subscribers only: Roe for Myokardia Inc 's Suppliers
Subscribers only: Return On Equity for MYOK's Customers




Companies with similar Return On Equity at Sep 30 2020, within Healthcare Sector ROE

Date modified: 2026-08-29T17:33:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.